OptiScan (OIL) 2021年年度报告「ASX」.pdf

《OptiScan (OIL) 2021年年度报告「ASX」.pdf》由会员分享，可在线阅读，更多相关《OptiScan (OIL) 2021年年度报告「ASX」.pdf（61页珍藏版）》请在三个皮匠报告上搜索。

1、Optiscan Imaging Limited Appendix 4E Preliminary final report 1.Company details Name of entity:Optiscan Imaging Limited ABN:81 077 771 987 Reporting period:For the year ended 30 June 2021 Previous period:For the year ended 30 June 2020 2.Results for announcement to the market$Revenues from ordinary

2、activities down 25.3%to 889,526 Loss from ordinary activities after tax attributable to the owners of Optiscan Imaging Limited up 20.5%to (2,126,695)Loss for the year attributable to the owners of Optiscan Imaging Limited up 20.5%to (2,126,695)Dividends There were no dividends paid,recommended or de

3、clared during the current financial period.Comments The loss for the consolidated entity after providing for income tax amounted to$2,126,695(30 June 2020:$1,765,353).Financial performance During the financial year ending 30 June 2021(FY21),the consolidated entity generated ordinary revenue of$889,5

4、26 from sales,system rentals and the provision of services(2020:$1,190,712)and other income of$1,651,928(2020:$785,714).Other income comprised$511,979 received from the BioMedtech Horizons Program which forms part of the Federal Governments Medical Research Future Fund to support the Oral Cancer Stu

5、dy at the University of Melbourne,Melbourne Dental School(MDS Oral Cancer Trial).The consolidated entity also recorded research and development incentive income of$847,324,an increase of$146,082 from the previous corresponding period(2020:$701,242).Total expenses for FY21 increased to$4,668,149,an i

6、ncrease of$926,370 from the corresponding period(2020:$3,741,779).These expenses include those relating to the cost of the MDS Oral Cancer Trial;preparations for the application to the United States Food&Drug Administration(FDA)to market the InVivage device for sale in the United States(US based con